PROBE TRIAL (Pilot Rilpivirine Observational Evaluation) Monocenter, national, prospective, open label, pilot, proof-of-concept study on the use of rilpivirine as substitutive agent for the HAART nucleosidic backbone in virologic suppressed patients.

Trial Profile

PROBE TRIAL (Pilot Rilpivirine Observational Evaluation) Monocenter, national, prospective, open label, pilot, proof-of-concept study on the use of rilpivirine as substitutive agent for the HAART nucleosidic backbone in virologic suppressed patients.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2016

At a glance

  • Drugs Rilpivirine (Primary) ; Darunavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms PROBE
  • Most Recent Events

    • 20 Feb 2016 Primary endpoint has been met, (Non-inferiority of the virological response between treatment groups according to FDA snapshot approach, at 24 and 48 weeks), according to results published.
    • 20 Feb 2016 Results published in the JAIDS.
    • 24 Oct 2015 Status changed from recruiting to active, no longer recruiting, according to results published.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top